Stemness-Inducing Nucleic Acid for Ethical Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing stemness in cells face challenges related to ethical concerns with embryonic stem cells and limited efficacy in regenerative therapies, necessitating a more effective and ethical approach for increasing or maintaining stemness in cells.
Innovation Solution
A nucleic acid molecule encoding an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 1, or a vector including this nucleic acid, is used to induce stemness in cells, which can include a gene or polynucleotide, and is delivered via vectors like plasmids or viruses to enhance stemness and differentiation capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If embryonic stem cells are used as therapeutic agents, then pluripotency and therapeutic potential are maximized, but ethical issues arise regarding harm to early human life
Solution Approach 1:
The patent uses induced pluripotent stem cells (iPSCs) as a copy or alternative to embryonic stem cells. iPSCs are generated by reprogramming somatic cells to express pluripotency, thereby replicating the therapeutic potential of embryonic stem cells without the ethical controversy of embryo destruction. This copying approach allows the system to achieve the same function (pluripotency-based therapy) through a different, ethically acceptable mechanism.
2Object-affected harmful factors
If induced pluripotent stem cells are used instead of embryonic stem cells, then ethical issues are resolved, but the efficiency and efficacy of regenerative therapy are reduced
Solution Approach 1:
The patent introduces specific parameters or factors (such as growth factors, cytokines, or genetic modifications) that enhance the differentiation capacity and functional maturity of iPSCs. By adjusting these parameters during culture and differentiation protocols, the therapeutic efficacy of iPSCs is improved to match or exceed that of embryonic stem cells, thereby resolving the efficacy concern while maintaining ethical advantages.
3Object-affected harmful factors
If direct differentiation of other cells is pursued instead of using stem cells, then ethical issues are avoided, but the differentiation capacity and versatility are limited
Solution Approach 1:
The patent employs preliminary reprogramming actions to convert somatic cells into iPSCs before differentiation. This preliminary step endows the cells with pluripotency, which then enables versatile differentiation into multiple cell types. By performing this preliminary reprogramming action, the system gains the adaptability and differentiation capacity of stem cells while avoiding the ethical issues of using actual embryonic stem cells.
4Adaptability or versatility
If gene introduction methods are used for tissue regeneration, then therapeutic options are expanded, but the complexity of delivery systems increases
Solution Approach 1:
The patent uses viral vectors (such as lentivirus or adeno-associated virus) as intermediary carriers to deliver reprogramming genes into somatic cells. These viral intermediaries efficiently transduce the target cells and enable stable integration or expression of the reprogramming factors, thereby simplifying the overall gene introduction process while expanding therapeutic options for tissue regeneration.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present specification relates to a factor for inducing stemness in cells and a method of increasing or maintaining stemness in cells by using the same. The factor for inducing stemness in cells and the method of increasing or maintaining stemness in cells by using the same, according to an aspect, have an effect of increasing or maintaining proliferation capacity and stemness in cells, and can be effectively used for increasing therapeutic efficiency and mass culturing, and thus can be used as a cell therapeutic agent. Also, the factor and the method have an effect of exhibiting regenerative efficacy in target tissues upon administration to a living body as a gene therapeutic agent.